Testing for EGFR mutations in patients with NSCLC is the current standard of care in Canada since 2013, following the introduction of EGFR tyrosine kinase inhibitors (TKIs) in 2010 [5]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.